Accelerating Agentic ERP transformation at Bavarian Nordic

Adding Amgen’s Imdelltra (tarlatamab) to AstraZeneca’s Imfinzi (durvalumab) as first-line maintenance treatment reduced the risk of death by 58% compared with Imfinzi alone in extensive-stage small cell lung cancer, according to results from the Phase III DeLLphi-305 trial presented at ESMO 2026.

Hansa Biopharma’s imlifidase (Idefirix) achieved 90% graft failure-free survival one year after transplantation in highly sensitized kidney patients in the European post-authorization PAES study. The results were presented as a late-breaking abstract at ASN Kidney Week 2026 in Denver.

Genmab’s antibody-drug conjugate rinatabart sesutecan (Rina-S) significantly improved both progression-free and overall survival compared with chemotherapy in the Phase 3 RAINFOL-02 trial in women with platinum-resistant ovarian cancer.

Spago Nanomedical’s Board of Directors has resolved to apply for delisting from the Nasdaq First North Growth Market, subject to approval at an extraordinary general meeting on November 19, 2026. The goal is to make it easier to finance the next phase of Tumorad’s development with long-term specialist investors.

A new international study led from Lund University shows that brain changes associated with Alzheimer’s disease may affect the prognosis in ALS. In the long term, the findings could lead to more reliable individual prognoses and better-designed clinical trials.

Danish biotech Saniona has submitted an Investigational New Drug (IND) application to the US FDA for SAN2465 in major depressive disorder. If the FDA clears the application, the company expects to start a Phase 1 trial before the end of 2026.

Proximity, capital and the ability to scale. When Nordic Life Science reported from life science hubs across Europe, from cities such as Gothenburg, Stockholm, Basel and Barcelona to the Flanders region and the UK as a whole, the same strengths, and the same bottlenecks, kept coming up.